270 related articles for article (PubMed ID: 30372881)
1. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
Li Y; Lv S; Ning H; Li K; Zhou X; Xv H; Wen H
Biomed Pharmacother; 2018 Dec; 108():1775-1782. PubMed ID: 30372881
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of
Liu Z; Dang C; Xing E; Zhao M; Shi L; Sun J
DNA Cell Biol; 2019 Nov; 38(11):1366-1373. PubMed ID: 31633393
[TBL] [Abstract][Full Text] [Related]
3. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis.
Wang J; Jia J; Zhou L
Neoplasma; 2020 Nov; 67(6):1279-1292. PubMed ID: 32787433
[TBL] [Abstract][Full Text] [Related]
5. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
6. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.
Feng Y; Zou W; Hu C; Li G; Zhou S; He Y; Ma F; Deng C; Sun L
Arch Biochem Biophys; 2017 Jun; 623-624():20-30. PubMed ID: 28495512
[TBL] [Abstract][Full Text] [Related]
7. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
Guo Y; Yue P; Wang Y; Chen G; Li Y
Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway.
Chen Z; Gao YJ; Hou RZ; Ding DY; Song DF; Wang DY; Feng Y
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):171-180. PubMed ID: 30657558
[TBL] [Abstract][Full Text] [Related]
9. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
10. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
12. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
13. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C.
Li G; Yang F; Gu S; Li Z; Xue M
Mol Med Rep; 2016 Jan; 13(1):572-8. PubMed ID: 26573417
[TBL] [Abstract][Full Text] [Related]
15. Let-7b attenuates cisplatin resistance and tumor growth in gastric cancer by targeting AURKB.
Han X; Zhang JJ; Han ZQ; Zhang HB; Wang ZA
Cancer Gene Ther; 2018 Dec; 25(11-12):300-308. PubMed ID: 30237418
[TBL] [Abstract][Full Text] [Related]
16. MiR-187 influences cisplatin-resistance of gastric cancer cells through regulating the TGF-β/Smad signaling pathway.
Zhu QL; Li Z; Lv CM; Wang W
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9907-9914. PubMed ID: 31799659
[TBL] [Abstract][Full Text] [Related]
17. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
Fang Q; Chen X; Zhi X
Med Sci Monit; 2016 Oct; 22():3506-3513. PubMed ID: 27694794
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of LncRNA CASC2 mediated the cell viability, apoptosis and autophagy of colon cancer cells by sponging miR-19a via NF-κB signaling pathway.
Zhang P; Pan Y; Sun J; Pan G
Int J Exp Pathol; 2021 Jun; 102(3):163-171. PubMed ID: 33983643
[TBL] [Abstract][Full Text] [Related]
20. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis.
Li M; Zhang YY; Shang J; Xu YD
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4185-4191. PubMed ID: 31173289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
